TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20007794

Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen 500 mg and ibuprofen 150 mg per tablet (Maxigesic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen 500 mg per tablet alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen 150 mg per tablet alone
Number of subjects: 0
Study: 18560649

Group type: EXPERIMENTAL
Intervention: Gysi prosthesis (simplified procedure with anatomic teeth)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gerber prosthesis (comprehensive method with lingualized teeth)
Number of subjects: 20
Study: 16292136

Group type: EXPERIMENTAL
Intervention: HbF-mode analyses
Number of subjects: 20

Group type: COMPARATOR
Intervention: HbA-mode analyses (control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy adults (control)
Number of subjects: 20
Study: 12182272

Group type: EXPERIMENTAL
Intervention: 30 mg fluoxetine per day
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: 60 mg fluoxetine per day
Number of subjects: 989

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study: 10190822

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate, 20 mg/d
Number of subjects: 248

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 248
Study: 8846544

Group type: EXPERIMENTAL
Intervention: Anti-TNF alpha monoclonal antibodies (mabs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-1 blockade with IL-1 ra and soluble IL-1 R
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-T cell therapies
Number of subjects: 0
Study: 2178965

Group type: EXPERIMENTAL
Intervention: Theophylline (individually titrated dose)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Theophylline intake at 10 p.m.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Theophylline intake at 6 p.m. and 8 p.m.
Number of subjects: 26
Study: 7188910

Group type: EXPERIMENTAL
Intervention: Hydroderm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrokortison DAK
Number of subjects: 0
Study: 31810940

Group type: EXPERIMENTAL
Intervention: Repeated-dose RSB analgesia
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Preoperative BPI severity score
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Postoperative BPI severity score
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Preoperative BPI interference score
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Postoperative BPI interference score
Number of subjects: 56
Study: 28402454

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 160-80-40 mg subcutaneously
Number of subjects: 91

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2.5 mg/kg/day
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 91
Study: 26506378

Group type: EXPERIMENTAL
Intervention: Bev-3.0 (96 kcal whey protein beverage with pH 3.0)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bev-7.0 (96 kcal whey protein beverage with pH 7.0)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gel-Acid (96 kcal whey protein gel)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gel-Heated (96 kcal whey protein gel)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON (0 kcal water)
Number of subjects: 12
Study: 23936977

Group type: EXPERIMENTAL
Intervention: Intramuscular depot medroxyprogesterone acetate (DMPA) therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Age >30 years
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Moderate to severe stages of endometriosis
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Severe pain prior to treatment
Number of subjects: 61
Study: 21299465

Group type: EXPERIMENTAL
Intervention: Pamidronate (60‐90 mg once a month for 1 year)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 177
Study: 20439555

Group type: EXPERIMENTAL
Intervention: Iron-fortified pandesal (hydrogen-reduced iron at 80 mg/kg, electrolytic iron at 80 mg/kg, or ferrous fumarate at 40 mg/kg)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Iron and VA-fortified pandesal
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: VA-fortified pandesal (at 490 RE/100 g)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Nonfortified flour (control group)
Number of subjects: 250
Study: 17194963

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET) for 8 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 37
Study: 15124072

Group type: EXPERIMENTAL
Intervention: brimonidine 0.2%
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: dorzolamide 2%
Number of subjects: 92
Study: 11808064

Group type: EXPERIMENTAL
Intervention: Neem mouthwash (with or without alcohol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neem mouthwash
Number of subjects: 0
Study: 9740926

Group type: EXPERIMENTAL
Intervention: Brompheniramine 12 mg
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Brompheniramine 8 mg
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 8056702

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 235
Study: 3395665

Group type: EXPERIMENTAL
Intervention: 25 mg oral dose of terodiline (Mictrol)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Deuterated drug as a covariate
Number of subjects: 8
Study: 31237713

Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin therapy
Number of subjects: 2933

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2933
Study: 27641967

Group type: EXPERIMENTAL
Intervention: Sitagliptin (50-100mg daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (diet and exercise)
Number of subjects: 41
Study: 25305273

Group type: EXPERIMENTAL
Intervention: Phytosterols intake (average 296 mg/d)
Number of subjects: 35597
Study: 22511572

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon plus bare-metal stenting (BMS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Taxus stent implantation
Number of subjects: 48
Study: 21896019

Group type: EXPERIMENTAL
Intervention: Participatory tool for discussing dogs' quality-of-life
Number of subjects: 170

Group type: COMPARATOR
Intervention: Normal consultations (control group)
Number of subjects: 170
Study: 19455117

Group type: EXPERIMENTAL
Intervention: Extracorporeal albumin dialysis (ECAD) plus standard medical therapy
Number of subjects: 597

Group type: COMPARATOR
Intervention: Standard medical therapy only
Number of subjects: 597
Study: 16932229

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus NMBAs (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional therapy plus placebo (n = 18)
Number of subjects: 36
Study: 15384020

Group type: EXPERIMENTAL
Intervention: DMSA, 2.5 mg/kg/d for 8 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 44
Study: 11566047

Group type: EXPERIMENTAL
Intervention: 50 microg GHRH administered as a single intravenous bolus
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 microg GHRH administered as five repetitive boluses within 1 h
Number of subjects: 0
Study: 9740479

Group type: EXPERIMENTAL
Intervention: Clonidine (transdermal patch)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 8092427

Group type: EXPERIMENTAL
Intervention: Amoxicillin (AX)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177

Group type: COMPARATOR
Intervention: Penicillin G (PG)
Number of subjects: 177
Study: 3345614

Group type: EXPERIMENTAL
Intervention: Sodium indomethacin (pH 8.2, 12%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium naproxen (pH 9.6, 40%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (pH 4.8, 8%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gels (various pH levels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acid forms of naproxen and indomethacin
Number of subjects: 0
Study: 31673835

Group type: EXPERIMENTAL
Intervention: Radiomics-based model
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Combined radiomic-clinical model
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 113
Study: 30177674

Group type: EXPERIMENTAL
Intervention: Spinal ropivacaine (7-15 mg) in Group S (BMI <25)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Spinal ropivacaine (7-15 mg) in Group M (25 ≤ BMI <30)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Spinal ropivacaine (7-15 mg) in Group L (BMI ≥30)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Incidence of hypotension
Number of subjects: 405
Study: 27102553

Group type: EXPERIMENTAL
Intervention: EPO + TXA (10,000 IU EPO daily subcutaneous injections on preoperative days 1-4 and postoperative days 1-3; 15 mg/kg TXA 10 min prior to incision)
Number of subjects: 62

Group type: COMPARATOR
Intervention: TXA (15 mg/kg TXA 10 min prior to incision)
Number of subjects: 62
Study: 26423182

Group type: EXPERIMENTAL
Intervention: Aripiprazole (target dose 10 mg [maximum 15 mg] daily) for 12 weeks
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 24220412

Group type: EXPERIMENTAL
Intervention: Improved decompressive craniectomy
Number of subjects: 131

Group type: COMPARATOR
Intervention: Routine decompressive craniectomy (Control)
Number of subjects: 131
Study: 21039405

Group type: EXPERIMENTAL
Intervention: Botox (BOT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neurobloc/Myobloc (NBC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pure saline (Control)
Number of subjects: 18
Study: 18511702

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5343

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 5343

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg
Number of subjects: 5343

Group type: EXPERIMENTAL
Intervention: Salmeterol plus fluticasone propionate
Number of subjects: 5343

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate and salmeterol
Number of subjects: 5343
Study: 12521408

Group type: EXPERIMENTAL
Intervention: Unfiltered Natural American Spirit
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unfiltered Irie bidi
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unfiltered Sher bidi
Number of subjects: 10

Group type: COMPARATOR
Intervention: Participant's own brand
Number of subjects: 10
Study: 9884248

Group type: COMPARATOR
Intervention: Neoral (N)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Tacrolimus (FK)
Number of subjects: 97
Study: 7640502

Group type: EXPERIMENTAL
Intervention: Poria‐Polyporus Anti‐diarrhea Mixture (PPAM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Smicta
Number of subjects: 60
Study: 2744633

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 500 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Choline magnesium trisalicylate (CMT) 500 mg
Number of subjects: 10
Study: 736748

Group type: EXPERIMENTAL
Intervention: Predicted cancer chemotherapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Non-predicted or no surgical adjuvant chemotherapy
Number of subjects: 135
Study: 29189311

Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg, 800 mg, 1200 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 29772131

Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture (GAA) - 6 sessions every 15 days, using anti-aggression and stomach points.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Body Acupuncture (GBA) - 24 sessions total, using bilateral L14, LIll, ST25, ST36, SP6, SP9, CV12, and CV6 points, two times a week.
Number of subjects: 50
Study: 25958769

Group type: EXPERIMENTAL
Intervention: Usual care plus brief self-hypnosis training (two × 90-minute groups at around 32 and 35 weeks' gestation; daily audio self-hypnosis CD)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Usual care plus brief self-hypnosis training
Number of subjects: 680
Study: 23376050

Group type: EXPERIMENTAL
Intervention: Lower body stabilization
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Biaxial pencil
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Assigned grip height pencil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Regular pencil
Number of subjects: 14
Study: 20652703

Group type: EXPERIMENTAL
Intervention: Tanespimycin suspension for injection
Number of subjects: 17

Group type: COMPARATOR
Intervention: Tanespimycin injection (Cremophor-based formulation)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Overall treatment with tanespimycin (both formulations)
Number of subjects: 17
Study: 18942713

Group type: EXPERIMENTAL
Intervention: Early maturing girls
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Baseline Tanner stage
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Sexual maturation stages in boys
Number of subjects: 283
Study: 17076973

Group type: EXPERIMENTAL
Intervention: Mebendazole 200 mg three times for 1 day
Number of subjects: 122

Group type: COMPARATOR
Intervention: Tinidazole 50 mg/kg in a single dose
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 122

Group type: COMPARATOR
Intervention: Tinidazole
Number of subjects: 122
Study: 14657227

Group type: EXPERIMENTAL
Intervention: FOLFIRI followed by FOLFOX6 (arm A)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: FOLFOX6 followed by FOLFIRI (arm B)
Number of subjects: 220

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 220

Group type: COMPARATOR
Intervention: FOLFOX6
Number of subjects: 220
Study: 11718213

Group type: EXPERIMENTAL
Intervention: GM-CSF for 3 days, five days prior to chemotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 60
Study: 9109740

Group type: EXPERIMENTAL
Intervention: Physostigmine (30 mg transdermal patch, releasing about 6 mg over 24 hours)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (transdermal patch)
Number of subjects: 19
Study: 7959241

Group type: COMPARATOR
Intervention: Extracorporeal shockwave lithotripsy (ESWL) alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ESWL with adjuvant bile acid treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (ESWL alone and ESWL with bile acids)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bile salt treatment
Number of subjects: 50
Study: 26595213

Group type: EXPERIMENTAL
Intervention: Ambient temperature at 25°C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambient temperature at 15, 20, and 25°C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambient temperature decrease from 25 to 5°C
Number of subjects: 0
Study: 24850228

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI) 45-405 mg every 2-4 weeks
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI)
Number of subjects: 931
Study: 22408034

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily for 3 months)
Number of subjects: 909

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 909
Study: 20580206

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 111

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 111

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 111
Study: 19687351

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: EXP3179
Number of subjects: 153
Study: 16509835

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg each morning)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sertraline and Placebo
Number of subjects: 62
Study: 12623986

Group type: EXPERIMENTAL
Intervention: Cyclosporine therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Calcineurin inhibitor-free regimen
Number of subjects: 57
Study: 11799734

Group type: EXPERIMENTAL
Intervention: 4% articaine + epinephrine 1:200,000
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 3% mepivacaine without vasoconstrictor
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 3% prilocaine + felypressin 1:1,850,000
Number of subjects: 45
Study: 9057731

Group type: COMPARATOR
Intervention: Circumcision with placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Circumcision with Emla
Number of subjects: 87
Study: 8198628

Group type: EXPERIMENTAL
Intervention: Nylestriol 2 mg/2 wk
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Nylestriol 1 mg/2 wk
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo/2 wk
Number of subjects: 283
Study: 3085844

Group type: EXPERIMENTAL
Intervention: Supine position with bumetanide 1 mg intravenously
Number of subjects: 12

Group type: COMPARATOR
Intervention: Upright position with bumetanide 1 mg intravenously
Number of subjects: 12
Study: 31906925

Group type: EXPERIMENTAL
Intervention: Pamphlet
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Oral information session
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Pamphlet and oral information session
Number of subjects: 254

Group type: COMPARATOR
Intervention: No information
Number of subjects: 254
Study: 30054245

Group type: EXPERIMENTAL
Intervention: 5% Benzoyl peroxide (BPO)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 4% Chlorhexidine gluconate (CHG)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 5% Benzoyl peroxide (BPO) and 4% Chlorhexidine gluconate (CHG)
Number of subjects: 80
Study: 26962308

Group type: EXPERIMENTAL
Intervention: Propofol/Midazolam/Remifentanil (PMR)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Propofol/Midazolam/Ketamine (PMK)
Number of subjects: 32
Study: 24905063

Group type: EXPERIMENTAL
Intervention: Estradiol and progestin therapy
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Estradiol, progestin, and testosterone therapy
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control women
Number of subjects: 215
Study: 22395196

Group type: EXPERIMENTAL
Intervention: Nesiritide group (received conventional treatment plus nesiritide infusion at 0.0075-0.015 μg·kg(‐1)·min(‐1) for 10-15 hours, total 0.5-1.0 mg once daily for 13 days)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nesiritide group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (received only conventional treatment for AHF)
Number of subjects: 140
Study: 20089489

Group type: EXPERIMENTAL
Intervention: Losartan 0.7 to 1.4 mg/kg per day
Number of subjects: 306

Group type: COMPARATOR
Intervention: Amlodipine 0.1 to 0.2 mg/kg per day up to 5 mg/d
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 18928837

Group type: EXPERIMENTAL
Intervention: Conventional inferior alveolar technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gow-Gates technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vazirani-Akinosi technique
Number of subjects: 40
Study: 16106336

Group type: EXPERIMENTAL
Intervention: Individualized motivational intervention (IMI) provided by nurses with telephone reminders 1 week after the intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study: 12587767

Group type: EXPERIMENTAL
Intervention: Fluoridated sugar (10 ppm fluoride)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Normal sugar
Number of subjects: 176
Study: 10363572

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (1.8 or 3.6 g/day)
Number of subjects: 11
Study: 7727768

Group type: EXPERIMENTAL
Intervention: Low-dose combination (ZDV 150 mg and ddl 134 mg, daily)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Moderate-dose combination (ZDV 300 mg and ddl 334 mg, daily)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: High-dose combination (ZDV 600 mg and ddl 500 mg, daily)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: ddl monotherapy (ddl 500 mg, daily)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: All treatment arms combined
Number of subjects: 126
Study: 2201495

Group type: EXPERIMENTAL
Intervention: Max EPA fish oil supplement (15 capsules/day with meals)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no Max EPA)
Number of subjects: 22
Study: 6160020

Group type: EXPERIMENTAL
Intervention: Kwell Shampoo (gamma benzene hexachloride; lindane)
Number of subjects: 15

Group type: COMPARATOR
Intervention: RID (pyrethrin-based pediculicide)
Number of subjects: 15
Study: 31319786

Group type: EXPERIMENTAL
Intervention: BC+R (provider advice and cessation assistance + three sessions of in-person counseling)
Number of subjects: 89

Group type: COMPARATOR
Intervention: BC (provider advice and cessation assistance)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: BC+R
Number of subjects: 89
Study: 31564142

Group type: EXPERIMENTAL
Intervention: Single thick Kirschner wire (K-wire)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Dual thin Kirschner wires
Number of subjects: 290
Study: 27740719

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 467

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 467
Study: 25869369

Group type: EXPERIMENTAL
Intervention: Responsive stimulation
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Enhanced nutrition
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Usual standard of care
Number of subjects: 1489
Study: 23528655

Group type: COMPARATOR
Intervention: Standard regimen (2 × 15 J/cm²‐clean‐2 × 15 J/cm²)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Simplified regimen (3 × 15 J/cm²‐no clean)
Number of subjects: 41